Raul Colodner

Raul Colodner, Ph.D. Dr. Raul Colodner is the Director of the Laboratory Medicine Department of Emek Medical Center and the Regional Laboratories of Clalit Health Services in Northern Israel. He was born in Buenos Aires, Argentina in 1955. He obtained his Master degree in Laboratory Medicine Sciences and Biochemistry from the University of Buenos Aires in 1978. His first position was as young researcher in the Argentinian National Institute of Microbiology. Since 1979 he lives in Israel. In 2003 he obtained his Ph.D. degree in Clinical Microbiology from the Union University at Cincinnati, USA and a Master Degree in Health Administration from Ben Gurion University in 2008. In the last 30 years he has been involved in diagnostics, clinical research and teaching, as a senior clinical microbiologist, chair of Microbiology laboratory and since 2006 Director of Laboratory Medicine Department of Emek Medical Center and the Regional Laboratories of Clalit Health Services in Northern Israel. In 1993 he was a visiting researcher at the Mount Sinai Hospital in New York City and the Long Island Jewish Medical Center in New Hyde Park, NY. Dr. Colodner's academic experience includes teaching Medical Microbiology in several academic institutions, including the Rappaport Medical School of Technion Institute in Haifa, Sheinbron Nursing School of Tel Aviv University, Tel Hi College and Yezreel Valley College. He has authored and co-authored 79 peer-reviewed articles and presented 84 abstracts at international meetings. Between 2004 and 2010 he was the Israel delegate for the European Antimicrobial Resistance Surveillance System and was an invited speaker in more than 40 professional meetings. Dr. Colodner has tutored more than 20 Graduate students in basic sciences and Master Thesis. He is a member of the Editorial Board of two International and one National journal. He has received two prices for outstanding research. His main fields of research are bacterial resistance to antibiotics, rapid diagnostic methods in bacteriology, and the use of probiotics for the prevention and treatment of infectious diseases. Following an outbreak in 1996, he isolated and described for the first time the new emerging pathogen Vibrio vulnificus Biotype 3.